Piper Jaffray Expands Biotechnology Investment Banking Team With Addition Of Chris Collins

Piper Jaffray Expands Biotechnology Investment Banking Team With Addition Of Chris Collins

Piper Jaffray (NYSE:PJC), a leading investment bank and asset management firm, today announced that Chris Collins has joined the firm as a principal in its biotechnology investment banking group. His experience includes more than 14 years in financial services including 12 years focused on the biotechnology industry. He will be based in the firm's San Francisco office. 

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.